Hypertension in the elderly: How to treat patients in 2013?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 7-8, 2013, Pages 409-416

  Tomasik, Tomasz ^a   Gryglewska, Barbara ^a   Windak, Adam ^a   Grodzicki, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antihypertensive drugs; Guidelines; Hypertension; Lifestyle modification; Old age

Indexed keywords

ALCOHOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARBOHYDRATE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; POTASSIUM; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AEROBIC EXERCISE; AGED; AGING; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; AWARENESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM EXAMINATION; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DELPHI STUDY; DIET THERAPY; DISEASE ASSOCIATION; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EXERCISE; EXERCISE TOLERANCE; FAINTNESS; FRUIT; HEART ARRHYTHMIA; HEART INFARCTION; HOME BLOOD PRESSURE MEASUREMENT; HOME MONITORING; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LABORATORY TEST; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MASKED HYPERTENSION; MEDICAL SOCIETY; MEDICAL SPECIALIST; MORTALITY; OBESITY; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PHYSICIAN; POLAND; PRACTICE GUIDELINE; PREVALENCE; PROTEIN CALORIE MALNUTRITION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SALT INTAKE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VEGETABLE; WEIGHT REDUCTION; WHITE COAT HYPERTENSION; HEALTH EDUCATION; HEALTH PROMOTION; LIFESTYLE; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; EXERCISE; HEALTH EDUCATION; HEALTH PROMOTION; HUMANS; HYPERTENSION; LIFE STYLE; PATIENT EDUCATION AS TOPIC; POLAND; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; SOCIETIES, MEDICAL;

EID: 84885154648     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. [Statistical Yearbook of the Republic of Poland 2011]. http://www.stat. gov.pl/cps/rde/xbcr/gus/rs-rocznik-statystyczny-rp-2011.pdf. Polish. Accessed May 7, 2013.
2. Zdrojewski T, Wiecek A, Grodzicki T, et al. [Dissemination, awareness, and efficacy of antihypertensive treatment in individuals over 65 years of age in Poland]. In: Mossakowska M, Wiecek A, Błedowski P, eds. [Medical, psychological, sociological, and economical aspects of aging in Poland]. Warszawa, Poland: Termedia Wydawnictwa Medyczne; 2012; 155-168. Polish.
3. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 1887-1898.
4. Grodzicki T, Gryglewska B, Tomasik T, Windak A. [Management of elderly patients with arteria hypertension]. Łódź, Poland: Aktis; 2012. Polish.
5. Widecka K, Grodzicki T, Narkiewicz K, et al. [Management of arterial hypertension in 2011. Guidelines of the Polish Society of Arterial Hypertension]. Nadciśnienie Tetnicze. 2011; 15: 55-82. Polish.
6. Parati G, Ochoa JE, Lombardi C, et al. Assessment and interpretation of blood pressure variability in a clinical setting. Blood Press. 2013 Apr 29. [Epub ahead of print].
7. Li Y, Boggia J, Thijs L, et al.; International Database on Ambulatory Blood Pressure Monitoring in relation to Cardiovascular Outcomes Investigators. Is blood pressure during the night more predictive of cardiovascular outcome than during the day? Blood Press Monit. 2008; 13: 145-147.
8. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011; 378: 1219-1230.
9. Krause T, Lovibond K, Caulfield M, et al.; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011; 343: d4891.
10. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-1187.
11. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009; 27: 923-934.
12. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly; A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011; 5: 259-352.
13. Evidence-Based Recommendations Task Force 2012 for the 2013 Recommendations. CHEP 2013 Recommendations. http: //www.hypertension. ca/chep-dp2. Accessed June 21, 2013.
14. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press. 2013 Jun 18. [Epub ahead of print].
15. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European Guidelines on Hypertension Management: A European Society of Hypertension Task Force document. Blood Press. 2009; 18: 308-347.
16. Ogihara T, Saruta T, Rakugi H, et al.; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension. 2010; 56: 196-202.
17. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31: 2115-2127.
18. The Systolic Blood Pressure Intervention Trial (SPRINT). http: //clinicaltrials. gov/ct2/show/NCT01 206 062. Accessed June 18, 2013.
19. Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013: CD007 654.
20. Smith SR, Klotman PE, Svetkey LP. Potassium chloride lowers blood pressure and causes natriuresis in older patients with hypertension. J Am Soc Nephrol. 1992; 2: 1302-1309.
21. Fotherby MD, Potter JF. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients. J Hypertens. 1992; 10: 1403-1408.
22. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med. 2001; 161: 685-693.
23. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013; 2: e004 473.
24. Appel DW, Aldrich TK. Smoking cessation in the elderly. Clin Geriatr Med. 2003; 19: 77-100.
25. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009; CD000 028.
26. Butt DA, Mamdani M, Austin PC, et al RH. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int. 2013 Apr 24. [Epub ahead of print].
27. Messerli FH, Sulicka J, Gryglewska B. Treatment of hypertension in the elderly. N Engl J Med. 2008; 359: 972-973.
28. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011; 13: 639-643.
29. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009; CD001 841.
30. Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011; 57: 590-600.
31. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). SHEP cooperative research group. JAMA. 1991; 265: 3255-3264.
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
33. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011; 306: 2588-2593.
34. Beckett N, Peters R, Tuomilehto J, et al.; HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ. 2011; 344: d7541.
35. Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich). 2011; 13: 667-675.
36. Gianni M, Bosch J, Pogue J, et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J. 2007; 28: 1382-1388.
37. Mohamed MA, Weir MR. Renin angiotensin system inhibition in the older person: a review. Clin Geriatr Med. 2009; 25: 245-257.
38. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms. J Nutr Health Aging. 2008; 12: 480-485.
39. Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich). 2011; 13: 677-686.
40. Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging. 2006; 23: 131-155.
41. Ma C, Cao J, Lu XC, et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. J Geriatr Cardiol. 2012; 9: 252-257.
42. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011; 13: 687-689.
43. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350: 757-764.
44. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352: 1347-1351.
45. Staessen JA, Thijs L, Richart T, et al. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension. 2011; 57: e6-e7.
46. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998; 279: 1903-1907.
47. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006; 174: 1737-1742.
48. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417-2428.
49. Ogihara T, Matsuzaki M, Umemoto S, et al.; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res. 2012; 35: 441-448.
50. Václavík J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT). Hypertension. 2011; 57: 1069-1075.
51. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-1559.
52. Novartis announces termination of ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment. Novartis Global Communications. December 20, 2011. www.novartis.com/newsroom/ media-releases/en/2011/1572 562.shtml. Accessed January 9, 2012.
53. Gryglewska B. How can we improve the effectiveness of treatment in elderly hypertensives? Blood Press Suppl. 2005; 2: 46-49.
54. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122: 290-300.
55. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents, a meta-analysis. Hypertension. 2010; 55: 399-407.